Below are key documents, including commissioning policies and guidance, that provide the latest information on best practice in diagnosing and treating ovarian cancer.
- Achieving world class cancer outcomes: a strategy for England 2015-2020 - In July 2015 a new cancer strategy was published for England. It sets out new ambitions around early diagnosis, with 95 per cent of patients to receive a diagnosis within four weeks of first going to see their GP, improvements in surgery and ensuring women with ovarian cancer are offered testing for the BRCA gene mutation.
- NHS England service specification for gynaecological cancer - Sets out the standards specialist ovarian cancer services should be commissioned to.
- Clinical Commissioning Policy: genetic testing for BRCA1 and BRCA2 mutations - NHS England commissions genetic testing for anyone with a ten per cent or higher risk of having a BRCA mutation. Up to one in six women with ovarian cancer have a genetic mutation, therefore all women with non-mucinous ovarian cancer are now eligible for genetic testing. Read more on familial ovarian cancer.
- Living with and beyond ovarian cancer: a descriptive summary of responses to a pilot of Patient Reported Outcome Measures for gynaecological cancer - Survey data showing how supported patients felt during treatment and their health and wellbeing at the point of answering the survey.
England, Wales and Northern Ireland
- NICE Clinical Guideline 122 - Ovarian cancer: the recognition and initial management of ovarian cancer - Sets out the referral process for women with suspected ovarian cancer, covering the referral pathway up to and including first line treatment.
- NICE Quality Standard 18 - Ovarian Cancer - Sets out what high-quality care looks like for women with ovarian cancer.
- NICE Clinical Guideline 164 – Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer - Guidance on testing for BRCA1 and BRCA2 mutations which lowers the threshold for testing to a ten per cent or higher risk of having a genetic mutation.
- SIGN 135 – Management of epithelial ovarian cancer - Sets out the referral process for women with suspected ovarian cancer, covering the referral pathway up to and including first line treatment as well as genetic testing for women with ovarian cancer and treatment for relapsed disease.
- Scottish referral guideline for suspected cancer - Provides advice on initial referral and testing for a range of cancers, including ovarian.